Quantcast

Cambridge Biomedical Recognized for 4th Year as One of the Top 100 Women Led Businesses in Massachusetts

November 8, 2013

For the fourth year in a row, Cambridge Biomedical Inc, a specialized contract research and diagnostic testing laboratory based in Brighton, MA, has been recognized by the Boston Business Journal as one of the top women-led businesses in Massachusetts.

Boston, Massachusetts (PRWEB) November 08, 2013

The Commonwealth Institute and Boston Business Journal hosted the 4th Annual Top 100 Women-Led Businesses Awards Ceremony on November 1st at the Renaissance Hotel Boston. Cambridge Biomedical was recognized for being placed 78th on the list.The annual rankings, which are based on total revenue, recognize outstanding women business leaders in Massachusetts.

Barbara Osband, Cambridge Biomedical's President and CEO, stressed that from its initial founding in 1997, Cambridge Biomedical has served the needs of life sciences companies. Under

her leadership, the company has put into place innovative developments that offer our clients unrivaled customer service. We are proud that our cutting-edge science and strong

organization has been recognized for its initial growth. With an ever-expanding client base, we look forward to even greater successes in the years to come.

Cambridge Biomedical

Since 1997, Cambridge Biomedical has provided a customer focused approach to support our clients by providing a diverse range of bioanalytical services from pre-clinical to post market. These include assay development, optimization, validation and diagnostic testing. Conveniently located in Boston to support the North East pharmaceutical development market, yet with a national and global reach. We deliver personalized project management and rapid turnaround times to expedite your development pipeline.

Contact:

1320 Soldiers Field Road

Boston, MA 02135

T: 617.456.0700

salesinfo(at)cambridgebiomedical(dot)com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11308371.htm


Source: prweb



comments powered by Disqus